News

Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

NASDAQ

Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.